Back to Search Start Over

Tazarotene scales ahead in the psoriasis cost-effectiveness stakes

Authors :
Carlene Todd
Source :
Inpharma Weekly. :7
Publication Year :
1998
Publisher :
Springer Science and Business Media LLC, 1998.

Abstract

Although psoriasis is perceived to have a limited effect on the cost of US healthcare, the reality is very different. Psoriasis is a persistent and progressive skin disorder that affects about 6 million people in the US, with 250 000 new cases diagnosed every year. Depending on disease severity, annual outpatient care can cost $US1400-$US6600 per patient, representing a total national cost of $US3.2 billion/year in the US. According to investigators from Health Economics Research, New Jersey, US, the high cost of care for selected patients with mild-to-moderate psoriasis can be reduced by using the new topical retinoid tazarotene.1At the recent 56th Annual Meeting of the American Dermatology Association [Orlando, US; March 1998], the investigators presented the results of a pharmacoeconomic model of monotherapy with either tazarotene, fluocinonide or calcipotriol for patients with mild-to-moderate stable plaque psoriasis. *

Details

ISSN :
11738324
Database :
OpenAIRE
Journal :
Inpharma Weekly
Accession number :
edsair.doi.dedup.....70fe40c2d6cc759213c9fb18058c95fc
Full Text :
https://doi.org/10.2165/00128413-199811350-00011